β-Cell Function and Diabetes Outcomes 1 Year After Stopping Oral Baricitinib Immunotherapy for Type 1 Diabetes
Authors' conclusion
The benefits of oral baricitinib in type 1 diabetes wane over 48 weeks following treatment cessation.
Study context
- Population
- Recent-onset T1D, BANDIT trial participants followed after study drug ceased at week 4888 completed week 96
- Participants
- 91 participants
- Comparison
- Baricitinib vs placebo, outcomes after treatment cessation
- Baricitinibn = 58
- Placebon = 30reference
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
C-peptide response to mixed meal · week 72
P = 0.015
Further findings
C-peptide response to mixed meal · week 96
P = 0.336
Insulin dose, HbA1c, continuous glucose monitoring (CGM) measures · follow-up
- No significant between-group differences during follow-up
C-peptide change from baseline after cessation, by age (Baricitinib)
- Children (n = 32): C-peptide decreased relative to baseline, P = 0.022
- 0.09 pmol/mL
- Adults (n = 28): full preservation of β-cell function
- Post hoc
Glucagon response to mixed meal
- Baricitinib did not resolve paradoxical glucagon increase after a mixed meal
Effector memory CD8+ T cells · week 96
- Decreased frequency and cytokine signaling seen at week 48 resolved by week 96
Original publication
β-Cell Function and Diabetes Outcomes 1 Year After Stopping Oral Baricitinib Immunotherapy for Type 1 Diabetes. Diabetes Care. Published 21 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →